Results 121 to 130 of about 11,703 (213)

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nature Medicine, 2023
H. Soliman, D. Hogue, H. Han, Blaise Mooney, R. Costa, Marie Catherine Lee, B. Niell, Angela Williams, A. Chau, Shannon Falcon, A. Soyano, A. Armaghani, N. Khakpour, R. Weinfurtner, S. Hoover, J. Kiluk, C. Laronga, M. Rosa, H. Khong, B. Czerniecki   +19 more
semanticscholar   +1 more source

Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR

Molecular Therapy: Oncology
This study reports a strategy to overcome immune escape of tumors during viro-immunotherapy due to tumor heterogeneity. We pursued a dual-targeting approach of epidermal growth factor receptor (EGFR) and cellular mesenchymal epithelial transition factor (
Martin A. Boos, Oliver Seifert, Stefanie Sawall, Jessica Genz, Annika Huber, Ilse Hofmann, Roland E. Kontermann, Guy Ungerechts, Dirk M. Nettelbeck   +8 more
doaj   +1 more source

Oncolytic virotherapy: the questions and the promise

Oncolytic Virotherapy, 2013
Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms.
openaire   +3 more sources

Current Development of Virotherapy in Breast Cancer: A Brief Review

Acta Medica Bulgarica
Breast cancer is the cancer with the greatest incidence in the world by 2020. This cancer has a high mortality rate, has the capability of metastasizing, and causes damage to important organs of the human body.
Sasmana I., Putri P., Dewi N., Supadmanaba I., Wihandani D.   +4 more
doaj   +1 more source

Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma. [PDF]

Ann Med Surg (Lond)
Aleem MR, Baloch K, Shahid M, Talha SS.
europepmc   +1 more source

Engineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death. [PDF]

Mol Ther Oncol
Chen X, Chen Y, Ping Y.
europepmc   +1 more source

Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection. [PDF]

Cell Mol Immunol
Dieli C, Di Simone M, Dieli F, Meraviglia S.   +3 more
europepmc   +1 more source

Oncolytic Viruses for Cancer Therapy in Dogs. [PDF]

Viruses
Neymysheva DO, Ilyinskaya GV, Sarkisova VA, Mukhina EA, Romanen-Kova SA, Chumakov PM.   +5 more
europepmc   +1 more source

Harnessing oncogenic signaling to enhance oncolytic virotherapy: Lessons from EPAC-encoding vaccinia virus. [PDF]

Mol Ther Oncol
Boulton S, Singh S, Bell JC.
europepmc   +1 more source

Fire in an Icy Desert: Oncolytic Virotherapy for Pancreatic Adenocarcinoma. [PDF]

Pharmaceutics
Rossetto A, Reale A.
europepmc   +1 more source